Novel Regulator of Acylated Ghrelin, CF801, Reduces Weight Gain, Rebound Feeding after a Fast, and Adiposity in Mice by Martin K. Wellman et al.
ORIGINAL RESEARCH
published: 25 September 2015
doi: 10.3389/fendo.2015.00144
Edited by:
Francisco Gracia-Navarro,
University of Cordoba, Spain
Reviewed by:
Jeff S. Davies,
Swansea University, UK
Riccarda Granata,
University of Turin, Italy
Manuel D. Gahete,
University of Cordoba, Spain
*Correspondence:
Alfonso Abizaid,
Department of Neuroscience,
Carleton University, 1125 Colonel By
Drive, 329 Life Science Research
Building, Ottawa, ON K1S 5B6,
Canada
alfonso_abizaid@carleton.ca
Specialty section:
This article was submitted to Systems
and Translational Endocrinology,
a section of the journal
Frontiers in Endocrinology
Received: 19 June 2015
Accepted: 01 September 2015
Published: 25 September 2015
Citation:
Wellman MK, Patterson ZR,
MacKay H, Darling JE, Mani BK,
Zigman JM, Hougland JL and
Abizaid A (2015) Novel regulator of
acylated ghrelin, CF801, reduces
weight gain, rebound feeding after a
fast, and adiposity in mice.
Front. Endocrinol. 6:144.
doi: 10.3389/fendo.2015.00144
Novel regulator of acylated ghrelin,
CF801, reduces weight gain, rebound
feeding after a fast, and adiposity
in mice
Martin K. Wellman1, Zachary R. Patterson1, Harry MacKay 1, Joseph E. Darling2,
Bharath K. Mani3,4,5, Jeffrey M. Zigman3,4,5, James L. Hougland2 and Alfonso Abizaid1*
1 Department of Neuroscience, Carleton University, Ottawa, ON, Canada, 2 Department of Chemistry, Syracuse University,
Syracuse, NY, USA, 3 Department of Internal Medicine, Division of Hypothalamic Research, The University of Texas South-
western Medical Center, Dallas, TX, USA, 4 Department of Internal Medicine, Division of Endocrinology and Metabolism,
The University of Texas Southwestern Medical Center, Dallas, TX, USA, 5 Department of Psychiatry, The University of Texas
Southwestern Medical Center, Dallas, TX, USA
Ghrelin is a 28 amino acid hormonal peptide that is intimately related to the regulation
of food intake and body weight. Once secreted, ghrelin binds to the growth hormone
secretagogue receptor-1a, the only known receptor for ghrelin and is capable of activating
a number of signaling cascades, ultimately resulting in an increase in food intake and
adiposity. Because ghrelin has been linked to overeating and the development of obesity,
a number of pharmacological interventions have been generated in order to interfere
with either the activation of ghrelin or interrupting ghrelin signaling as a means to
reducing appetite and decrease weight gain. Here, we present a novel peptide, CF801,
capable of reducing circulating acylated ghrelin levels and subsequent body weight gain
and adiposity. To this end, we show that IP administration of CF801 is sufficient to
reduce circulating plasma acylated ghrelin levels. Acutely, intraperitoneal injections of
CF801 resulted in decreased rebound feeding after an overnight fast. When delivered
chronically, they decreased weight gain and adiposity without affecting caloric intake.
CF801, however, did cause a change in diet preference, decreasing preference for a high-
fat diet and increasing preference for regular chow diet. Given the complexity of ghrelin
receptor function, we propose that CF801, along with other compounds that regulate
ghrelin secretion, may prove to be a beneficial tool in the study of the ghrelin system,
and potential targets for ghrelin-based obesity treatments without altering the function of
ghrelin receptors.
Keywords: ghrelin, ghrelin-O-acyltransferase, ghrelin antagonist, weight loss, appetite, energy expenditure,
adiposity
Introduction
One potential target for the control of body weight and appetite is the gut–brain peptide ghrelin.
Ghrelin, a 28-amino-acid peptide produced in the X/A-like cells of the gastric oxyntic mucosa
lining the stomach, is a key regulator of both short- and long-term energy homeostasis (1–3).
Circulating ghrelin levels rise in anticipation of a meal and subside once the organism is satiated
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(4–7). Furthermore, ghrelin has been shown to regulate several
physiological processes, including glucose metabolism (8–12),
insulin secretion (8, 13, 14), gastric emptying (15), cell prolif-
eration (16, 17), memory (18), stress (19–22), anxiety (18, 19,
22–25), and reward (26–29). Acutely, ghrelin promotes food
intake through interactions with a subset of distinct first order
hypothalamic nuclei (2, 3, 30–34) and injections of ghrelin result
in vigorous feeding bouts (35–37). Ghrelin contributes to long-
term energy homeostasis by increasing bodyweight and adiposity,
presumably through a reduction of lipid oxidation (3, 21, 38, 39).
Ghrelin increases motivation to obtain food (27–29, 40) and also
increases the preference for highly palatable foods by acting in the
VTA (28, 29, 41, 42).
The ability of ghrelin to carry out its physiological pro-
cesses relies on its affinity for the growth hormone secretagogue
receptor-1a (GHSR-1a), the only known ghrelin receptor. GHSR-
1a is widely expressed in both rodents and humans, with high-
est expression found in the hypothalamus and pituitary gland,
both areas heavily invested in energy homeostasis and growth
hormone secretion (43). Within the hypothalamus, GHSR-1a
expression is most concentrated to the arcuate nucleus (43–45), a
region important in the regulation of food intake, metabolism and
energy homeostasis (3, 46, 47). Interestingly, activation of GHSR-
1a requires a post-translational modification of the proghrelin
peptide (1), a characteristic unique to ghrelin amongst all other
metabolically active hormones. Specifically, ghrelin must be acy-
lated on the hydroxyl group of the third serine (Ser3) residue with
an n-octanoic acid, or other medium-chain fatty acid (MCFA)
containing 6–12 carbons, in order to bind to and activateGHSR-1a
(1). Modification with an n-octanoyl group induces a conforma-
tional flexibility that accommodates the geometric specificity of
GHSR-1a’s binding pocket (48).
The enzyme responsible for the acylation of the mature ghre-
lin peptide is called ghrelin-O-acyltransferase, or GOAT (49,
50), which belongs to a superfamily of enzymes known as
the membrane-bound-O-acyltransferases (MBOATs) (51). GOAT
expressionhas been demonstrated inmany rat,mouse, andhuman
tissues, including the ghrelin producing X/A-like cells of the gas-
tric oxyntic mucosa lining the stomach (52–54). To date, GOAT
is the only known enzyme capable of acylating, and therefore
activating ghrelin, as evidenced by structure–activity analyses of
ghrelin mimetic substrates and inhibitors as well as by studies
demonstrating the complete absence of acylated ghrelin in GOAT
null mice (49, 55). As such, GOAT has become a target for the
development of drugs to curb appetite and reduce weight gain via
a reduction in acylated ghrelin concentrations (55–59). Indeed, a
number of compounds that reduce GOAT activity are successful
in decreasing weight gain and adiposity. For instance, daily treat-
ment with GO-CoA-TAT, a peptide GOAT inhibitor, was effective
in reducing weight gain and adiposity in mice while decreasing
acylated ghrelin concentrations (60).
In this paper, we present CF801, a synthetic peptide that was
thought to be a novel GOAT inhibitor, and one that decreases
plasma concentrations of acylated ghrelin in vitro and in vivo.
While we demonstrate that CF801 is not an efficient inhibitor
of GOAT octanoylation activity, CF801 produced a number of
important metabolic effects, including a decrease in weight gain
and adiposity associated with changes in appetite and energy
expenditure associated with decreased ghrelin concentrations.
Materials and Methods
Design of CF801
An approach was undertaken to design a novel GOAT inhibitor,
resulting in a compound we named CF801. The first five amino
acids of CF801 derive from studies carried out in 2008 by Yang
et al., who examined the inhibitory effect of certain pentapeptides
(e.g., GSAFL-NH2) on GOAT using a microsomal assay (56).
While these peptides showed inhibitory activity on GOAT, it was
unlikely that the peptide could effectively cross membranes to
reach the endoplasmic reticulum lumen, where GOAT performs
its enzymatic reactions (50). In synthesizing CF801, we extended
and modified the original GSAFL-NH2 sequence with the addi-
tion of five more amino acids that correspond to amino acids
6–10 of the full-length ghrelin peptide. The addition of these
amino acids increases the similarity of CF801 to the non-acylated
ghrelin peptide sequence as well as provides an appropriate spacer
for attachment of additional modifications. The secondmodifica-
tion from the GSAFL-NH2 peptide was the addition of an HIV
trans-activator of transcription (Tat) sequence. CF801 contains
the following Tat sequence: RKKRRQRRR, with an amide group
retained on the C-terminus.
The full sequence of CF801 is as follows: GSAFLSPEHQRK
KRRQRRR-NH2, where the N-terminus has the standard free
amine group (–NH2). Variants of thismolecule can be synthesized
through the inclusion of (or perhaps exclusion of) additional
amino acids from the mature ghrelin protein molecule and/or
using variants of the Tat sequence or other cell-penetrating pep-
tides. CF801 was custom synthesized by Peptides International
(Louisville, KY, USA).
Cell-Based Ghrelin Secretion Assay
Ghrelin secretion studies were performed in stomach-derived
ghrelinoma (SG-1) cells, cultured as described previously (61,
62). Cells were plated at a density of 5 104 cells/mL/well on
to 24-well plates pre-coated with poly--lysine (day 0). On day
2, the cells were treated with the indicated concentrations of
test compound CF801, 24 h ahead of the test period and with
50μM sodium octanoate–bovine serum albumin (BSA), 16 h
ahead of the test period. On day 3, the medium was aspi-
rated and the cells were treated with the same concentrations of
CF801 in 500μL serum-free DMEM (Life Technologies, Grand
Island, NY, USA) supplemented with 5mM glucose and 50μM
sodium octanoate–BSA. After a 6-h incubation, the medium
was collected, placed on ice, and immediately centrifuged at
800 g for 5min. Hydrochloric acid was added to the super-
natant to achieve a final concentration of 0.1N (for stabiliza-
tion of acyl ghrelin) and stored at  80°C until analysis. Assay
for acyl ghrelin and total were performed using commercial
ELISA kits (EMD Millipore Corporation, Billerica, MA, USA)
according to the manufacturer’s instructions and read in a Pow-
erWave XS Microplate spectrophotometer (BioTek Instruments,
Inc., Winooski, VT, USA).
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Fluorescence-Based GOAT Activity Assay
The effects of CF801 on GOAT activity were examined using a
previously validated fluorescence-based assay, and in comparison
with octanoyl-(Dap3)-ghrelin (1–5)–NH2, a well characterized
GOAT inhibitor (56, 63). In this assay, membrane fractions from
Sf9 insect cells were transfected to express either human (hGOAT)
or mouse GOAT (mGOAT). Membranes fractions were thawed
on ice and passed through an 18-gage needle 10 times enriched
using a previously describedmethod (63). Assays were performed
with 20–30μg membrane protein (for hGOAT) and 60–80μg
membrane protein (for mGOAT), 1.5μM GSSFLCAcDan pep-
tide substrate, 500μM octanoyl-CoA, 0–10μMCF801, octanoyl-
(Dap3)-ghrelin (1–5)–NH2, or carrier control (50mM HEPES
pH= 7.0 or DMSO) and 50mM HEPES pH 7.0 in a total volume
of 50μL. All components with the exception of the acrylodan-
labeled peptide substrate were incubated in the reaction vessel for
30min prior to assay initiation. Assays were initiated by addition
of the acrylodanylated peptide substrate GSSFLCAcDan. Assays
were then incubated at room temperature for 1 h and stopped
by addition of 50μL of 20% acetic acid in isopropanol. Assays
were analyzed by reverse phase HPLC with fluorescence detec-
tion. Chromatogram analysis and integration of peptide substrate
and product peaks were performed using Chemstation for LC
(Agilent Technologies). The trials were run in triplicate, with
the % activity calculated as the integrated fluorescence intensity
of the octanoylated product in the CF801 or octanoyl-(Dap3)-
ghrelin (1–5)–NH2 run normalized by the same quantity for the
vehicle-only reaction.
In Vivo Animal Studies
Animals
In general, male C57BL/6J mice (The Jackson Laboratory, Bar
Harbor, ME, USA) weighing 20–25 g were used as experimen-
tal subjects. Throughout the duration of the studies, mice were
housed under standard laboratory conditions and received ad libi-
tum access to standard laboratory mouse chow and tap water.
Lights in the facility were set to go on and off at 12 h intervals with
the lights going on at 7:00 a.m. In some experiments, mice also
had ad libitum access to a high-fat diet containing 60% caloric
content from fat (TD 06414; Harlan Teklad, Indianapolis, IN,
USA) in addition to regular chow to measure dietary preferences.
All procedures were approved by the Carleton University Animal
Care Committee and followed the guidelines of the Canadian
Council on Animal Care.
Effects of CF801 on Plasma Ghrelin Concentrations
and Rebound Food Intake in Fasted Mice
Mice (n= 16) were singly housed and given free access to water
and regular chow for a 4-day baseline period. After this, mice
were assigned to one of three groups: vehicle (n= 5), CF801
low dose (n= 5; 11μmolkg 1 – LD), or CF801 high dose
(n= 6; 22μmolkg 1 – HD). These mice were injected intraperi-
toneally once a day for 4 days starting at 10:00 a.m. Following
4 days of treatment, animals were tested for rebound feeding
after a fast. To do this, we removed the food from each cage
1 h before lights out (6:00 p.m.), and food was returned to the
cage the following day 1 h after the last injection. Food intake
was then monitored every hour for 4 h to determine the effects
of CF801 on rebound feeding. Animals were then sacrificed
by rapid decapitation to collect trunk blood and other tissues.
Two samples were lost during sample collection, so the num-
ber of samples used to measure acylated ghrelin was reduced to
n= 14.
Tissue and Blood Analysis
Following the treatment or recovery periods, mice were killed by
rapid decapitation and plasma and tissue samples were collected.
To measure glucose levels, glucose strips attached to a Contour
glucose meter (Bayer Corp., Pittsburgh, PA, USA) were dipped
in trunk blood collected before being centrifuged. The remaining
trunk blood was collected in EDTA-coated tubes placed on ice
and centrifuged at 800 g for 15min to separate plasma from
red blood cells. Blood plasma was aliquoted separately to avoid
multiple freeze/thaw cycles and stored at  80°C until processed.
To protect the acylated ghrelin molecule, a 50μL aliquot of blood
plasma was treated with 2.7μL of 1.0N hydrochloric acid and
10μL of 100mM 4-(hydroxymercuric)benzoic acid prior to stor-
age. Plasma acylated ghrelin for all animals was measured using
an ELISA kit (Millipore). All samples analyzed had a coefficient
of variation<10%.
Effects of CF801 on Food Intake, Weight Gain, and
Adiposity
A second cohort of mice (n= 30) was acclimated to the labora-
tory conditions for 1week prior to the onset of the experiment.
Mice were housed individually and their body weight and food
intake was recorded daily for a baseline period of 10 days. Given
that ghrelin augments the intake of preferred diets (28), all mice
received ad libitum access to a high-fat diet (60% of calories com-
ing from fat), in addition to regular chow, to determine if CF801
altered dietary preference. Both chow and high-fat diet pellets
were provided daily to mice ad libitum in pre-weighed amounts.
Mice were then assigned to four different groups: non-injected
control (NIC; n= 7), vehicle (0.9% saline) (VEH; n= 7), low-
dose CF801 (11μmolkg 1 – LD; n= 8) and high-dose CF801
(22μmolkg 1 – HD; n= 8). Each day at 09:00 hours, mice were
weighed and their food intake (both chow and high-fat diet) was
recorded. After this, mice received an intraperitoneal injection
of either CF801 or saline (except for the non-injected controls).
Following the 13-day treatment period, half the animals in each
group were sacrificed, while the remaining mice were allowed to
recover from treatment. During the 8-day recovery period, mice
were granted ad libitum access to standard laboratory chow, high-
fat diet, and water, but did not receive any injections. At this point,
the remaining mice were sacrificed. Carcasses from all animals
were frozen and stored at 80°C until they were scanned for body
composition analyses. Immediately prior to analysis, all carcasses
were thawed to room temperature and weighed in order to obtain
measures relative to total carcass mass. EchoMRI carcass analyses
were performed at Health Canada, Nutrition Research Division
facilities using the EchoMRI-1100 (System ID EF-020) scanner.
Each carcass was analyzed separately and measurements of total
fat mass, total lean mass, and total water weight were obtained for
each mouse.
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Effects of CF801 on Energy Expenditure
Mice (n= 10) were housed individually and their bodyweight and
food intake was recorded daily for a baseline period of 10 days.
As in Experiment 1, all mice had ad libitum access to regular lab
chow and a high-fat diet (60% of calories coming from fat). At
the end of the baseline, mice were housed in metabolic chambers
(TSE Systems) for 48 h to examine metabolic rate using indirect
calorimetry prior to the onset of the drug treatment. While indi-
rect calorimetry measures were obtained throughout the 48-h
period, we only analyzed measurements in the last 24 h to allow
the animals to adjust to the chambers. Mice were then assigned
to one of two groups: vehicle (0.9% saline) (VEH; n= 5) and
CF801 (22μmolkg 1; n= 5). Each day at 09:00 hours, mice were
weighed and their food intake (both chow and high-fat diet) was
recorded, and then received an intraperitoneal injection of either
CF801 or saline. Drug treatment continued for 16 days. On the
eighth day, mice were again placed in the metabolic chambers for
48 h while still being monitored and injected with their respective
treatment to determine differences in metabolism produced by
the drug.
Statistical Analyses
In most experiments, group differences were analyzed using inde-
pendent samples t-tests or one-way ANOVAs followed by Fisher
LSD post hoc tests when significance was reported. Food intake
and weight gain data over time were analyzed using repeated
measures ANOVAs followed by post hoc one-way ANOVAs and
Fisher LSD.
Results
CF801 Inhibits Acyl Ghrelin Secretion In Vitro and
In Vivo
SG-1 cells are derived from stomach ghrelinomas induced by
expression of the SV40 large T-antigen under the preproghre-
lin promoter. These cells retain many of the features of ghrelin
cells within primary cultures of gastric mucosal cells from mice
(61). They also show elevated expression of both preproghrelin
and GOAT mRNA with high levels of acylated ghrelin synthesis
and secretion (61). In order to test CF801’s ability to reduce
acyl ghrelin secretion, we performed an in vitro cell-based assay
using an SG-1 cell line as previously described (61, 62). No sig-
nificant effects were found after a 6-h incubation period with
CF801 (p> 0.05). However, following a 24-h incubation, CF801
inhibited acyl ghrelin secretion from SG-1 cells with an IC50 of
347 40μM, based on log-dose versus response non-linear fit.
Significant decreases in secretion were found at concentrations of
100μM (p< 0.05) and 300μM (p< 0.05) CF801 (Figure 1).
To determine if CF801 also altered acylated ghrelin concen-
trations, we conducted a study where mice were injected daily
with saline or CF801 at one of two doses for 4 days. No effects
of CF801 on food intake or weight gain were observed during
the first 3 days of treatment (data not shown, p> 0.05). Before
the last day of treatment, mice were fasted overnight, treated with
their last injection, given access to food for 4 h and then sacrificed.
Figure 2A shows plasma acylated ghrelin concentrations in mice
treated with i.p. injections of saline, LD, or HD of CF801. As
FIGURE 1 | CF801 inhibits acyl ghrelin secretion from SG-1 cells following 24h of incubation. (A) depicts the in vitro assay design. (B) shows Acyl ghrelin
concentration in the culture medium collected during a 6 h test period following 24 h incubation at the indicated concentrations of CF801. All values are expressed as
meanSEM. *p<0.05, ***p<0.001 significant difference in acyl ghrelin concentrations with CF801 treatment when compared to untreated control (n= 6 wells).
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FIGURE 2 | Animals given HD CF801 displayed reduced levels of plasma acylated ghrelin following a 24h fast compared to vehicle-treated animals
(A). Average grams of regular laboratory chow consumed following a 24-h fast upon refeeding (B), and blood glucose measured from trunk blood (C). All values are
expressed as meanSEM. *p<0.05 relative to VEH-injected controls.
shown in the figure, CF801 caused a dose-dependent decrease
in plasma ghrelin concentrations that was statistically significant
[F(2,24)= 2.90 p< 0.05, partial eta2= 0.22] in mice treated with
the high dose (p< 0.05 Fisher LSD). This decrease in acylated
ghrelinwas also associatedwith a lower amount of food consumed
by mice treated with the high dose of CF801 during the first
hour of refeeding [see Figure 2B; F(2,24)= 2.394, p< 0.05, partial
eta2= 0.22, p< 0.05]. This was in correlation with acyl ghrelin
concentrations (r= 0.492, p< 0.05). No significant effects were
seen at any other time point examined (p> 0.05). Nevertheless,
there was a significant overall dose-dependent treatment effect on
the total amount of chow consumed during the 4-h period of food
access after the fast [F(2,24)= 4.527, partial eta2= 0.411; p> 0.05].
This effect was statistically significant when examining differ-
ences in total chow consumed between the HD and saline treated
groups (p< 0.01, Fisher LSD). No significant differences were
observed between the groups in blood glucose concentrations
[F(1,15)= 1.105, p> 0.05; see Figure 2C].
CF801 Does Not Serve as an Effective Inhibitor of
Ghrelin Octanoylation by GOAT
To test the potential that CF801’s ability to reduce acyl ghrelin
secretion in SG-1 cells is due to direct inhibition of GOAT-
catalyzed ghrelin octanoylation, we incubated CF801 with both
the human and mouse isoforms of the GOAT enzyme under
assay conditions previously described (63), with the potent GOAT
inhibitor octanoyl-(Dap3)-ghrelin (1–5)–NH2 (56) examined in
parallel as a positive control for GOAT inhibition. In this assay,
we tested concentrations comparable with those reported for
GO-CoA-Tat, which was reported to have an IC50 for GOAT of
<1μM (60). At concentrations up to 10μM, no inhibition was
seen with CF801 incubation [see Figure 3; hGOAT: F(3,8)= 1.251,
p> 0.05; mGOAT: F(3,8)= 0.139, p> 0.05], while robust inhibi-
tion was seen with the control [IC50 of 20 2 nM and 80 10 nM
with hGOAT andmGOAT, respectively; hGOAT: F(3,8)= 485.023,
p< 0.05, all doses less than vehicle with p’s< 0.05 by Fisher’s LSD
post hoc; mGOAT: F(3,8)= 51.476, p< 0.05, all doses less than
vehicle with p’s< 0.05 by Fisher’s LSD post hoc]. This suggests that
the observed effects of CF801 in cell- and animal-based studies are
not caused by direct inhibition of ghrelin octanoylation by GOAT.
CF801 Treatment Reduces High-Fat Diet Intake
and Body Weight Gain Without Affecting Caloric
Intake
Given that CF801 decreased ghrelin concentrations and rebound
feeding, we decided to examine if CF801 affected weight gain and
food intake inmice that had access to a high-fat diet in addition to
regular chow. As illustrated in Figure 4, there were no differences
between any groups in the amount of calories consumed during
the baseline period [F(1,29)= 0.586, p> 0.05], treatment period
[F(1,29)= 0.783, p> 0.05], and recovery period [F(1,29)= 2.093,
p> 0.05]. It was evident, however, that mice preferred the high-fat
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A B 
FIGURE 3 | Percent activity of human GOAT (A) and mouse GOAT (B) (obtained from membrane fractions from Sf9 cells expressing hGOAT and
mGOAT, resepectively) when exposed to CF801 and octanoyl-(Dap3)-ghrelin (1–5)–NH2 using a fluorescence-based microsomal assay. GSSFLCAcDan
was used as an acylation target with fluorescence measured by reverse phase HPLC with fluorescence detection. CF801 had no effect on either hGOAT or mGOAT
acylation activity, while octanoyl-(Dap3)-ghrelin (1–5)–NH2 dose-dependently reduced GOAT activity. All values are expressed as meanSEM. ***p<0.001
compared to vehicle control.
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FIGURE 4 | Average daily (A) and overall average (B) caloric intake during the baseline, treatment, and recovery period. All values are expressed as the
meanSEM.
diet during the baseline period as they consumed a higher propor-
tion of calories from this diet than the calories consumed from
the regular chow diet (p< 0.05; see Figure 5). This diet prefer-
ence changed during the treatment period. In particular, animals
receiving high dose of CF801 consumed significantlymore regular
chow than animals in every other group as revealed by a one-
way ANOVA followed by Fisher LSD post hoc [see Figures 5A,B;
F(3,28)= 5.305, p< 0.05, partial eta2= 0.41]. In contrast, CF801
caused an overall significant dose-dependent decrease in the
intake of the high-fat diet [Figures 5C,D; F(3,29)= 6.788, p< 0.05,
partial eta2= 0.45]. Therewere no differences in high-fat diet con-
sumption between NIC animals and VEH-treated animals. Ani-
mals receiving LD CF801 treatment consumed significantly less
high-fat diet compared to both NIC and VEH groups (p’s< 0.05).
Animals receiving HD CF801 consumed significantly less high-
fat diet compared to both NIC and VEH groups (p’s< 0.05)
and tended to consume less than animals receiving LD CF801
(p= 0.073). Interestingly, in correlation with decreased intake of
the high calorie diet, mice treated with the high dose of CF801
showed a decrease in weight gain compared to mice treated with
saline or mice that were not injected at all as determined by a one
way ANOVA followed by Fisher LSD post hoc tests [Figures 5E,F;
F(3,29)= 3.098, p< 0.05, partial eta2= 0.271]. Mice given the low
dose of CF801 tended to have lower weight gain than control NIC
(p= 0.092) and VEH-treated mice (p= 0.065), but this difference
did not attain statistical significance. Nevertheless, post hoc tests
also revealed that therewere no differences inweight gain between
mice treated with the low dose versus mice treated with the high
dose of CF801 (p> 0.05).
CF801 Increases the Utilization of Fat as Fuel
Given that treatment with CF801 decreased weight gain with-
out altering caloric intake, we reasoned that perhaps CF801 was
exerting its effects at the metabolic level. To examine this, we
examined differences in the respiratory exchange ratio (RER)
of mice treated with the high dose of CF801 (n= 5) with that
of saline-treated mice (n= 5) after a week of daily injections.
While both groups of mice showed nearly identical RER during
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FIGURE 5 | Average daily (A) and overall average (B) chow consumption during baseline and treatment periods. Average daily (C) and overall average
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baseline period (p> 0.05), mice treated with CF801 displayed a
significant decrease in RER during the 4-h period that followed
the injection of the drug, an effect not seen in vehicle-treatedmice
[t(5)= 3.457, p< 0.05] (see Figure 6A).
CF801 Treatment Alters Body Composition
Metabolic efficiency, defined as the amount of weight gained
per calorie of energy consumed during a given time period,
was calculated for each mouse during the baseline and treat-
ment period. There were no differences in metabolic efficiency
between any groups during the baseline period (data not shown).
As illustrated in Figure 6B, there was a significant treatment
effect on metabolic efficiency throughout the treatment period
[F(1,29)= 9.086, p< 0.05, partial eta2= 0.522]. Post hoc anal-
yses revealed that animals receiving LD CF801 had signifi-
cantly lower metabolic efficiencies during the treatment period
compared to both NIC (p< 0.05) and VEH treated animals
(p< 0.05). Similarly, animals receiving HD CF801 showed signif-
icantly lower metabolic efficiencies during the treatment period
compared with both NIC (p< 0.05) and VEH-treated animals
(p< 0.05), but were no different than animals receiving LDCF801
(p> 0.05).
Given these changes in metabolic efficiency as well as the
decrease in RER observed in the calorimetry experiment, we
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hypothesized that CF801 treatment would result in less accumu-
lation of fat. To determine if this was the case, we conducted
EchoMRI analyses on every animal post-mortem to identify dif-
ferences in body composition as a function between groups. As
shown in Figures 6C,D, the amount of total fat mass was signif-
icantly lower in mice treated with the high dose of CF801, com-
pared to VEH injected animals right after the treatment period
[F(1,14)= 3.54, p> 0.05; partial eta2= 0.515] and this decrease was
more evident 2weeks after the treatment period was terminated
[F(1,15)= 15.18, p< 0.05 partial eta2= 0.805]. Mice receiving LD
CF801 treatment and sacrificed at the end of the treatment period
had lower fat mass compared to VEH-treated animals, but this
was not statistically significant (p.> 0.05), but animals from the
same group sacrificed 2weeks after the last treatment had lower
fatmass thanmice in theVEH andNIC sacrificed at the same time
point (p< 0.05). There were no differences between the groups in
lean bodymass or water mass (p> 0.05). Interestingly, there was a
significant effect of treatment on fatmass:leanmass ratio following
the recovery period [see Figures 6E,F; F(1,15)= 7.735, p< 0.05;
partial eta2= 0.678]. An LSD post hoc analysis revealed that ani-
mals receiving LDCF801 treatment tended to show a reduction in
fat mass:lean mass ratio following the recovery period compared
to VEH-treated animals (p= 0.058) and had a significantly lower
fatmass:leanmass ratio compared toNIC animals (p< 0.05). Sim-
ilarly, animals receiving HD CF801 showed a significantly lower
fat mass:lean mass ratio compared to both NIC animals (p< 0.05)
and VEH-treated animals (p< 0.05), but were no different than
animals treated with LD CF801 (p> 0.05). Furthermore, there
was a significant treatment effect on the fat mass:total mass ratio
following the recovery period [F(1,15)= 9.245, p< 0.05; partial
eta2= 0.716]. LSD post hoc analysis revealed that both LD andHD
CF801-treated animals had significantly lower fat mass:total mass
ratios compared to NIC animals (p’s< 0.05) and VEH-treated
animals (p’s< 0.05).
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Discussion
Given that ghrelin is one of the few peripherally circulating hor-
mones capable of stimulating food intake, ghrelin has become
a target for the pharmacological control of appetite and weight
gain. Many attempts have been made at interrupting the ghrelin
signaling system through the inhibition of ghrelin secretion (64),
neutralizing the mature ghrelin protein via vaccination (65) or
spiegelmer antagonism (66–68), and/or interrupting ghrelin sig-
naling at the level of GHSR-1a (19, 21, 29, 41, 69). An emerging
approach is the development of compounds that target GOAT
as a potential therapeutic agent for combating weight gain and
adiposity (56, 57, 59, 60). There are several advantages of targeting
GOAT for the treatment of obesity, such as the selectivity to the
targeted acylated ghrelin molecule, the uninterrupted constitu-
tive activity of GHSR-1a (presumably necessary for appropriate
growth hormone secretion) and the up regulation of unacylated
ghrelin (UAG). Finally, it has been suggested that UAG may itself
be a viable treatment option through counteracting the activity of
acylated ghrelin and improving insulin sensitivity (70, 71).
In this paper, we show that CF801, a modified decapeptide
similar in structure to the ghrelin peptide, reduces weight gain and
adiposity without affecting total caloric intake. This is reminiscent
of studies reporting that mice with targeted mutations to the
gene encoding the message for the GOAT enzyme do not gain
as much weight and store less adipose tissue when fed a high-
fat diet compared to WT mice (46). Similarly, GHSR-null mice
that do not respond to the acylated ghrelin product of GOAT
enzymatic activity have reduced respiratory quotient and reduced
metabolic efficiency, consume less food, and put on less weight,
particularly in the form of adipose tissue, when given a high-fat
diet (72). These findings are also similar to those from studies
where mice were treated with GO-CoA-Tat, a previously charac-
terized inhibitor of GOAT activity (60). Unlike GO-CoA-Tat, the
mechanism underlying these effects does not appear to involve
direct inhibition of GOAT octanoylation activity although it does
involve a reduction in ghrelin secretion. Furthermore, CF801 was
able to blunt the usual rebound eating response to a 24-h fast,
reminiscent to what had been shown previously for a known
GHSR antagonist (29).
One way in which CF801 could be decreasing weight gain and
adiposity is through a dietary change. Indeed, while CF801 did not
alter total caloric intake, it did affect the proportion of calories
mice consumed from a high-fat diet and those consumed from
laboratory chow diet. Looking at the baseline period, one can
observe thatmice generally preferred to consume the high-fat diet,
a trend that continued throughout the study in control animals.
CF801 treated mice, however, reduced their intake of the high-fat
diet, and increased their intake of chow diet. It is unclear if this
change in preference is due to an effect of the drug on preference
or palatability, but it is certainly not due to a change in overall
appetite as these mice ate enough to maintain their caloric intake
throughout the study. It is important to note that at the end of
the treatment period, there was a small spike in caloric intake
in CF801-treated animals, suggesting that appetite increases once
CF801 injections stop. This may indicate that CF801 is associated
with enhancing signals that promote satiety, or simply by reducing
ghrelin tone, but this needs to be studied further. The latter expla-
nation is supported by data from our first study, where we show
that mice repeatedly treated with CF801 decrease rebound food
intake following an overnight fast in a dose-dependent manner
and in correlation with acyl ghrelin concentrations in plasma.
Another way by which CF801 decreases weight gain and adi-
posity without affecting total caloric intake may be through a
change in metabolism. It is well known that ghrelin favors the
utilization of carbohydrates as a source of fuels as demonstrated
by ghrelin-induced increases in RER inmice receiving daily injec-
tions of ghrelin (3). Here, we show that repeated injections of the
higher dose of CF801 led to acute decreases in RER suggesting
that CF801 changesmetabolism favoring the utilization of lipids as
fuel. This may also explain why CF801-treated mice also showed
a lower proportion of body fat with no changes in lean or water
mass. This is also similar to the effects of daily injections of GO-
CoA-Tat, a treatment that also resulted in a reduction of overall fat
mass relative to control vehicle-treated mice (60).
As described above, CF801 produces its effects through a reduc-
tion in acyl ghrelin concentrations, but not through a direct
inhibition of GOAT activity. Using an in vitro cell-based assay,
we were able to detect significant reductions in acyl ghrelin
secretion from SG-1 cells following 24 h of incubation in 100μM
and 300μM of CF801. Our preliminary data indicated that at a
shorter incubation time of only 6 h, CF801 had no effect on acyl
ghrelin secretion (data not shown), even at the highest concen-
tration of 300μM. Although Tat-peptide conjugates have been
shown to attain maximal penetration within the first 3 h (73),
our specific combination of amino acids has not been directly
examined in this regard although time frames considerably above
3 h seemunlikely. Furthermore, stability of acylated ghrelinwithin
vesicles is not known, but does not preclude the possibility of
reserve acylated ghrelin packaged within secretory vesicles. Our
data suggest that CF801’s effects may not be by direct inter-
action with the GOAT enzyme. This is also suggested by the
lack of potency demonstrated by CF801 in the in vitro microso-
mal GOAT activity assay that directly assesses GOAT-catalyzed
octanoylation of ghrelin mimetic peptide substrates. In contrast
to the SG-1 cell-based assay and the effects of CF801 in vivo,
CF801 was not able to reduce GOAT activity, while the known
GOAT inhibitor octanoyl-(Dap3)-ghrelin (1–5)–NH2 showed a
significant reduction.
Given the high amino acid similarity between CF801 and
desacyl ghrelin, it is possible that CF801 acts like an analog of
desacyl ghrelin. Indeed, desacyl ghrelin and the cyclic desacyl
ghrelin analog AZP531 appear to have effects that are similar to
those of CF801, including the decrease in weight gain, ghrelin
secretion, and adipose tissue accumulation (74, 75). Alternatively,
CF801 may reduce acylated ghrelin simply by reducing GOAT
mRNA, and thus acyl ghrelin levels, without altering GOAT
activity at least in the way that this is tested in vitro. While the
mechanisms underlying these effects are not well understood, the
idea that CF801 works like desacyl ghrelin or its analogs is an
interesting contention as these are currently being proposed for
potential clinical treatments to curb obesity. Given that ghrelin
may be a hormone that is an important hormone in attenuating
the effects of stress (19, 76, 77) or those of acute insults(78),
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more studies are required to determine if reducing acyl ghrelin
concentrations with CF801 could have unwarranted side effects.
Nevertheless, decreasing acyl ghrelin concentration peripherally
withCF801 orwith other bona fideGOAT inhibitors,may prove to
be a desirable option for the treatment of obesity without affecting
the functionality of the ghrelin receptor in the CNS.
Acknowledgments
This project was supported by funds obtained from the Cana-
dian Institutes for Health Research (CIHR), Natural Sciences and
Engineering Research Council (NSERC), and Carleton University
(AA) CIHR (MOP106445), and NSERC (RGPIN341538), NSERC
CGSD Scholarship (ZP and MW), Ontario Graduate Schol-
arship (MW and HM), the Hilda and Preston Davis Foun-
dation Postdoctoral Fellowship in Eating Disorders Research
(BM), an International Research Alliance grant with the Novo
Nordisk Foundation Center for Basic Metabolic Research at
the University of Copenhagen (JZ), the Foundation for Prader-
Willi Research (JH), a National Science Foundation Predoctoral
Fellowship (DGE-1247399) (JD), and Syracuse University (JD
and JH). We thank Prof. Jef Boeke (NYU Langone Medical
Center) for the gift of a plasmid encoding the mouse GOAT
isoform.
References
1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin
is a growth-hormone-releasing acylated peptide from stomach. Nature (1999)
402:656–60. doi:10.1038/45230
2. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A
role for ghrelin in the central regulation of feeding. Nature (2001) 409:194–8.
doi:10.1038/35051587
3. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents.
Nature (2000) 407:908–13. doi:10.1038/35038090
4. Blum ID, Patterson Z, Khazall R, Lamont EW, Sleeman MW, Horvath TL, et al.
Reduced anticipatory locomotor responses to scheduledmeals in ghrelin recep-
tor deficient mice. Neuroscience (2009) 164:351–9. doi:10.1016/j.neuroscience.
2009.08.009
5. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A
preprandial rise in plasma ghrelin levels suggests a role in meal initiation in
humans. Diabetes (2001) 50:1714–9. doi:10.2337/diabetes.50.8.1714
6. Drazen DL, Vahl TP, D’Alessio DA, Seeley RJ, Woods SC. Effects of a fixed meal
pattern on ghrelin secretion: evidence for a learned response independent of
nutrient status. Endocrinology (2006) 147:23–30. doi:10.1210/en.2005-0973
7. LeSauter J, Hoque N, Weintraub M, Pfaff DW, Silver R. Stomach ghrelin-
secreting cells as food-entrainable circadian clocks. Proc Natl Acad Sci U S A
(2009) 106:13582–7. doi:10.1073/pnas.0906426106
8. Broglio F, Gottero C, Benso A, Prodam F, Destefanis S, Gauna C, et al. Effects of
ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty
acids load in humans. J Clin Endocrinol Metab (2003) 88:4268–72. doi:10.1210/
jc.2002-021940
9. Sun Y, Asnicar M, Smith RG. Central and peripheral roles of ghrelin on glucose
homeostasis. Neuroendocrinology (2007) 86:215–28. doi:10.1159/000109094
10. Gualillo O, Lago F, Dieguez C. Introducing GOAT: a target for obesity and
anti-diabetic drugs? Trends Pharmacol Sci (2008) 29:398–401. doi:10.1016/j.
tips.2008.06.003
11. Yada T, Dezaki K, Sone H, Koizumi M, Damdindorj B, Nakata M, et al. Ghrelin
regulates insulin release and glycemia: physiological role and therapeutic poten-
tial. Curr Diabetes Rev (2008) 4:18–23. doi:10.2174/157339908783502352
12. Chuang JC, Sakata I, Kohno D, Perello M, Osborne-Lawrence S, Repa JJ, et al.
Ghrelin directly stimulates glucagon secretion from pancreatic α-cells. Mol
Endocrinol (2011) 25:1600–11. doi:10.1210/me.2011-1001
13. McLaughlin T, Abbasi F, Lamendola C, Frayo RS, Cummings DE. Plasma
ghrelin concentrations are decreased in insulin-resistant obese adults relative
to equally obese insulin-sensitive controls. J Clin Endocrinol Metab (2004)
89:1630–5. doi:10.1210/jc.2003-031572
14. Dezaki K, Kakei M, Yada T. Ghrelin uses Galphai2 and activates voltage-
dependent K+ channels to attenuate glucose-induced Ca2+ signaling and
insulin release in islet beta-cells: novel signal transduction of ghrelin. Diabetes
(2007) 56:2319–27. doi:10.2337/db07-0345
15. Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, et al. Ghrelin
stimulates gastric acid secretion and motility in rats. Biochem Biophys Res
Commun (2000) 276:905–8. doi:10.1006/bbrc.2000.3568
16. Andreis PG, Malendowicz LK, Trejter M, Neri G, Spinazzi R, Rossi GP, et al.
Ghrelin and growth hormone secretagogue receptor are expressed in the rat
adrenal cortex: evidence that ghrelin stimulates the growth, but not the secre-
tory activity of adrenal cells. FEBS Lett (2003) 536:173–9. doi:10.1016/S0014-
5793(03)00051-6
17. Walker AK, Rivera PD,Wang Q, Chuang JC, Tran S, Osborne-Lawrence S, et al.
The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in
mice by increasing hippocampal neurogenesis.Mol Psychiatry (2015) 20:500–8.
doi:10.1038/mp.2014.34
18. Carlini VP, Monzón ME, Varas MM, Cragnolini AB, Schiöth HB, Scimonelli
TN, et al. Ghrelin increases anxiety-like behavior and memory retention in
rats. Biochem Biophys Res Commun (2002) 299:739–43. doi:10.1016/S0006-
291X(02)02740-7
19. Lutter M, Sakata I, Osborne-Lawrence S, Rovinsky SA, Anderson JG, Jung S,
et al. The orexigenic hormone ghrelin defends against depressive symptoms of
chronic stress. Nat Neurosci (2008) 11:752–3. doi:10.1038/nn.2139
20. Patterson ZR, Ducharme R, Anisman H, Abizaid A. Altered metabolic and
neurochemical responses to chronic unpredictable stressors in ghrelin receptor-
deficient mice. Eur J Neurosci (2010) 32:632–9. doi:10.1111/j.1460-9568.2010.
07310.x
21. Patterson ZR, Khazall R,MackayH, AnismanH, Abizaid A. Central ghrelin sig-
naling mediates the metabolic response of C57BL/6 male mice to chronic social
defeat stress. Endocrinology (2013) 154:1080–91. doi:10.1210/en.2012-1834
22. Spencer SJ, Xu L, Clarke MA, Lemus M, Reichenbach A, Geenen B, et al.
Ghrelin regulates the hypothalamic-pituitary-adrenal axis and restricts anxiety
after acute stress. Biol Psychiatry (2012) 72:457–65. doi:10.1016/j.biopsych.
2012.03.010
23. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Fujimiya M, et al. A
role of ghrelin in neuroendocrine and behavioral responses to stress in mice.
Neuroendocrinology (2001) 74:143–7. doi:10.1159/000054680
24. Currie PJ, Khelemsky R, Rigsbee EM, Dono LM, Coiro CD, Chapman CD, et al.
Ghrelin is an orexigenic peptide and elicits anxiety-like behaviors following
administration into discrete regions of the hypothalamus. Behav Brain Res
(2012) 226:96–105. doi:10.1016/j.bbr.2011.08.037
25. Carlini VP, VarasMM, Cragnolini AB, Schiöth HB, Scimonelli TN, de Barioglio
SR. Differential role of the hippocampus, amygdala, and dorsal raphe nucleus
in regulating feeding, memory, and anxiety-like behavioral responses to ghre-
lin. Biochem Biophys Res Commun (2004) 313:635–41. doi:10.1016/j.bbrc.2003.
11.150
26. Abizaid A, Liu ZW, Andrews ZB, Shanabrough M, Borok E, Elsworth JD, et al.
Ghrelin modulates the activity and synaptic input organization of midbrain
dopamine neurons while promoting appetite. J Clin Invest (2006) 116:3229–39.
doi:10.1172/JCI29867
27. Skibicka KP, Hansson C, Alvarez-Crespo M, Friberg PA, Dickson SL. Ghrelin
directly targets the ventral tegmental area to increase food motivation. Neuro-
science (2011) 180:129–37. doi:10.1016/j.neuroscience.2011.02.016
28. King SJ, Isaacs AM, O’Farrell E, Abizaid A. Motivation to obtain preferred
foods is enhanced by ghrelin in the ventral tegmental area. Horm Behav (2011)
60:572–80. doi:10.1016/j.yhbeh.2011.08.006
29. Perello M, Sakata I, Birnbaum S, Chuang JC, Osborne-Lawrence S, Rovinsky
SA, et al. Ghrelin increases the rewarding value of high-fat diet in an orexin-
dependent manner. Biol Psychiatry (2010) 67:880–6. doi:10.1016/j.biopsych.
2009.10.030
Frontiers in Endocrinology | www.frontiersin.org September 2015 | Volume 6 | Article 14410
Wellman et al. Ghrelin inhibitor and energy balance
30. Currie PJ, Mirza A, Fuld R, Park D, Vasselli JR. Ghrelin is an orexigenic and
metabolic signaling peptide in the arcuate and paraventricular nuclei. Am J
Physiol Regul Integr Comp Physiol (2005) 289:R353–8. doi:10.1152/ajpregu.
00756.2004
31. Date Y, Shimbara T, Koda S, Toshinai K, Ida T, Murakami N, et al. Peripheral
ghrelin transmits orexigenic signals through the noradrenergic pathway from
the hindbrain to the hypothalamus. Cell Metab (2006) 4:323–31. doi:10.1016/j.
cmet.2006.09.004
32. Seoane LM, López M, Tovar S, Casanueva FF, Señarís R, Diéguez C. Agouti-
related peptide, neuropeptide Y, and somatostatin-producing neurons are
targets for ghrelin actions in the rat hypothalamus. Endocrinology (2003)
144:544–51. doi:10.1210/en.2002-220795
33. Cowley MA, Smart JL, Rubinstein M, Cerdán MG, Diano S, Horvath TL, et al.
Leptin activates anorexigenic POMC neurons through a neural network in the
arcuate nucleus. Nature (2001) 411:480–4. doi:10.1038/35078085
34. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, et al. The
novel hypothalamic peptide ghrelin stimulates food intake and growth hormone
secretion. Endocrinology (2000) 141:4325–8. doi:10.1210/endo.141.11.7873
35. Healy JE, Bateman JL, Ostrom CE, Florant GL. Peripheral ghrelin stimulates
feeding behavior and positive energy balance in a sciurid hibernator. Horm
Behav (2011) 59:512–9. doi:10.1016/j.yhbeh.2011.01.013
36. Keen-Rhinehart E, Bartness TJ. Peripheral ghrelin injections stimulate food
intake, foraging, and food hoarding in Siberian hamsters. Am J Physiol Regul
Integr Comp Physiol (2005) 288:R716–22. doi:10.1152/ajpregu.00705.2004
37. Tang-Christensen M, Vrang N, Ortmann S, Bidlingmaier M, Horvath TL,
Tschöp M. Central administration of ghrelin and agouti-related protein (83-
132) increases food intake and decreases spontaneous locomotor activity in rats.
Endocrinology (2004) 145:4645–52. doi:10.1210/en.2004-0529
38. Choi K, Roh SG, Hong YH, Shrestha YB, Hishikawa D, Chen C, et al. The role
of ghrelin and growth hormone secretagogues receptor on rat adipogenesis.
Endocrinology (2003) 144:754–9. doi:10.1210/en.2002-220783
39. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, Nogueiras R, Perez-Tilve D,
Pfluger P, et al. Ghrelin action in the brain controls adipocytemetabolism. J Clin
Invest (2006) 116:1983–93. doi:10.1172/JCI25811
40. Egecioglu E, Jerlhag E, Salomé N, Skibicka KP, Haage D, Bohlooly-Y M, et al.
Ghrelin increases intake of rewarding food in rodents. Addict Biol (2010)
15:304–11. doi:10.1111/j.1369-1600.2010.00216.x
41. Chuang JC, Perello M, Sakata I, Osborne-Lawrence S, Savitt JM, Lutter M, et al.
Ghrelin mediates stress-induced food-reward behavior in mice. J Clin Invest
(2011) 121:2684–92. doi:10.1172/JCI57660
42. MerkesteinM, BransMA, Luijendijk MC, de Jong JW, Egecioglu E, Dickson SL,
et al. Ghrelin mediates anticipation to a palatable meal in rats. Obesity (Silver
Spring) (2012) 20:963–71. doi:10.1038/oby.2011.389
43. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum
CI, et al. A receptor in pituitary and hypothalamus that functions in growth
hormone release. Science (1996) 273:974–7. doi:10.1126/science.273.5277.974
44. Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJ, et al.
Distribution of mRNA encoding the growth hormone secretagogue receptor in
brain and peripheral tissues. Brain Res Mol Brain Res (1997) 48:23–9. doi:10.
1016/S0169-328X(97)00071-5
45. Zigman JM, Jones JE, Lee CE, Saper CB, Elmquist JK. Expression of ghre-
lin receptor mRNA in the rat and the mouse brain. J Comp Neurol (2006)
494:528–48. doi:10.1002/cne.20823
46. Kirchner H, Gutierrez JA, Solenberg PJ, Pfluger PT, Czyzyk TA, Willency JA,
et al. GOAT links dietary lipids with the endocrine control of energy balance.
Nat Med (2009) 15:741–5. doi:10.1038/nm.1997
47. AbizaidA,Horvath TL. Brain circuits regulating energy homeostasis.Regul Pept
(2008) 149:3–10. doi:10.1016/j.regpep.2007.10.006
48. Bednarek MA, Feighner SD, Pong SS, McKee KK, Hreniuk DL, Silva MV,
et al. Structure-function studies on the new growth hormone-releasing peptide,
ghrelin: minimal sequence of ghrelin necessary for activation of growth hor-
mone secretagogue receptor 1a. J Med Chem (2000) 43:4370–6. doi:10.1021/
jm0001727
49. Gutierrez JA, Solenberg PJ, Perkins DR,Willency JA, KniermanMD, Jin Z, et al.
Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad
Sci U S A (2008) 105:6320–5. doi:10.1073/pnas.0800708105
50. Yang J, BrownMS, Liang G, Grishin NV, Goldstein JL. Identification of the acyl-
transferase that octanoylates ghrelin, an appetite-stimulating peptide hormone.
Cell (2008) 132:387–96. doi:10.1016/j.cell.2008.01.017
51. HofmannK. A superfamily ofmembrane-boundO-acyltransferases with impli-
cations for wnt signaling. Trends Biochem Sci (2000) 25:111–2. doi:10.1016/
S0968-0004(99)01539-X
52. Stengel A, Goebel M, Wang L, Taché Y, Sachs G, Lambrecht NW. Differential
distribution of ghrelin-O-acyltransferase (GOAT) immunoreactive cells in the
mouse and rat gastric oxyntic mucosa. Biochem Biophys Res Commun (2010)
392:67–71. doi:10.1016/j.bbrc.2009.12.169
53. Sakata I, Yang J, Lee CE, Osborne-Lawrence S, Rovinsky SA, Elmquist JK,
et al. Colocalization of ghrelin O-acyltransferase and ghrelin in gastric mucosal
cells.Am J Physiol Endocrinol Metab (2009) 297:E134–41. doi:10.1152/ajpendo.
90859.2008
54. Lim CT, Kola B, Grossman A, Korbonits M. The expression of ghrelin O-
acyltransferase (GOAT) in human tissues. Endocr J (2011) 58:707–10. doi:10.
1507/endocrj.K11E-117
55. Darling JE, Zhao F, Loftus RJ, Patton LM, Gibbs RA, Hougland JL. Structure-
activity analysis of human ghrelin O-acyltransferase reveals chemical deter-
minants of ghrelin selectivity and acyl group recognition. Biochemistry (2015)
54:1100–10. doi:10.1021/bi5010359
56. Yang J, Zhao TJ, Goldstein JL, Brown MS. Inhibition of ghrelin O-
acyltransferase (GOAT) by octanoylated pentapeptides. Proc Natl Acad Sci U
S A (2008) 105:10750–5. doi:10.1073/pnas.0805353105
57. Garner AL, Janda KD. A small molecule antagonist of ghrelin O-acyltransferase
(GOAT). Chem Commun (Camb) (2011) 47:7512–4. doi:10.1039/c1cc11817j
58. Garner AL, Janda KD. Cat-ELCCA: a robust method to monitor the fatty acid
acyltransferase activity of ghrelin O-acyltransferase (GOAT). Angew Chem Int
Ed (2010) 49:9630–4. doi:10.1002/anie.201003387
59. Zhao F, Darling JE, Gibbs RA, Hougland JL. A new class of ghrelin O-
acyltransferase inhibitors incorporating triazole-linked lipid mimetic groups.
Bioorg Med Chem Lett (2015) 25(14):2800–3. doi:10.1016/j.bmcl.2015.05.009
60. Barnett BP, Hwang Y, Taylor MS, Kirchner H, Pfluger PT, Bernard V, et al.
Glucose and weight control in mice with a designed ghrelin O-acyltransferase
inhibitor. Science (2010) 330:1689–92. doi:10.1126/science.1196154
61. Zhao TJ, Sakata I, Li RL, Liang G, Richardson JA, Brown MS, et al. Ghrelin
secretion stimulated by β1-adrenergic receptors in cultured ghrelinoma cells
and in fasted mice. Proc Natl Acad Sci U S A (2010) 107:15868–73. doi:10.1073/
pnas.1011116107
62. Mani BK, Chuang JC, Kjalarsdottir L, Sakata I, Walker AK, Kuperman A,
et al. Role of calcium and EPAC in norepinephrine-induced ghrelin secretion.
Endocrinology (2014) 155:98–107. doi:10.1210/en.2013-1691
63. Darling JE, Prybolsky EP, Sieburg M, Hougland JL. A fluorescent peptide
substrate facilitates investigation of ghrelin recognition and acylation by
ghrelin O-acyltransferase. Anal Biochem (2013) 437:68–76. doi:10.1016/j.ab.
2013.02.013
64. Pérez-Tilve D, González-Matías L, Alvarez-Crespo M, Leiras R, Tovar S,
Diéguez C, et al. Exendin-4 potently decreases ghrelin levels in fasting rats.
Diabetes (2007) 56:143–51. doi:10.2337/db05-0996
65. Zorrilla EP, Iwasaki S, Moss JA, Chang J, Otsuji J, Inoue K, et al. Vaccination
against weight gain. Proc Natl Acad Sci U SA (2006) 103:13226–31. doi:10.1073/
pnas.0605376103
66. Helmling S, Maasch C, Eulberg D, Buchner K, Schröder W, Lange C, et al.
Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc
Natl Acad Sci U S A (2004) 101:13174–9. doi:10.1073/pnas.0404175101
67. Kobelt P, Helmling S, Stengel A, Wlotzka B, Andresen V, Klapp BF, et al.
Anti-ghrelin spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic
effects of peripheral ghrelin in rats. Gut (2006) 55:788–92. doi:10.1136/gut.
2004.061010
68. Shearman LP, Wang SP, Helmling S, Stribling DS, Mazur P, Ge L, et al. Ghrelin
neutralization by a ribonucleic acid-SPM ameliorates obesity in diet-induced
obese mice. Endocrinology (2006) 147:1517–26. doi:10.1210/en.2005-0993
69. Moulin A, Ryan J, Martinez J, Fehrentz JA. Recent developments in ghre-
lin receptor ligands. ChemMedChem (2007) 2:1242–59. doi:10.1002/cmdc.
200700015
70. Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti M, et al. Non-
acylated ghrelin counteracts themetabolic but not the neuroendocrine response
to acylated ghrelin in humans. J Clin Endocrinol Metab (2004) 89:3062–5.
doi:10.1210/jc.2003-031964
71. Gauna C, Meyler FM, Janssen JA, Delhanty PJ, Abribat T, van Koetsveld
P, et al. Administration of acylated ghrelin reduces insulin sensitivity,
whereas the combination of acylated plus unacylated ghrelin strongly improves
Frontiers in Endocrinology | www.frontiersin.org September 2015 | Volume 6 | Article 14411
Wellman et al. Ghrelin inhibitor and energy balance
insulin sensitivity. J Clin Endocrinol Metab (2004) 89:5035–42. doi:10.1210/jc.
2004-0363
72. Zigman JM, Nakano Y, Coppari R, Balthasar N, Marcus JN, Lee CE, et al. Mice
lacking ghrelin receptors resist the development of diet-induced obesity. J Clin
Invest (2005) 115:3564–72. doi:10.1172/JCI26002
73. Jones SW, Christison R, Bundell K, Voyce CJ, Brockbank SM, Newham P, et al.
Characterisation of cell-penetrating peptide-mediated peptide delivery. Br J
Pharmacol (2005) 145:1093–102. doi:10.1038/sj.bjp.0706279
74. Delhanty PJ, Neggers SJ, van der Lely AJ. Mechanisms in endocrinology:
ghrelin: the differences between acyl- and des-acyl ghrelin. Eur J Endocrinol
(2012) 167:601–8. doi:10.1530/EJE-12-0456
75. Delhanty PJ, Huisman M, Baldeon-Rojas LY, van den Berge I, Grefhorst A,
Abribat T, et al. Des-acyl ghrelin analogs prevent high-fat-diet-induced dysreg-
ulation of glucose homeostasis. FASEB J (2013) 27:1690–700. doi:10.1096/fj.12-
221143
76. Abizaid A, Anisman H. Gut feelings about depression. J Psychiatry Neurosci
(2014) 39:364–6. doi:10.1503/jpn.140276
77. Spencer SJ, Emmerzaal TL, Kozicz T, Andrews ZB. Ghrelin’s role in
the hypothalamic-pituitary-adrenal axis stress response: implications for
mood disorders. Biol Psychiatry (2015) 78:19–27. doi:10.1016/j.biopsych.2014.
10.021
78. Andrews ZB, Erion D, Beiler R, Liu ZW, Abizaid A, Zigman J, et al. Ghre-
lin promotes and protects nigrostriatal dopamine function via a UCP2-
dependent mitochondrial mechanism. J Neurosci (2009) 29:14057–65. doi:10.
1523/JNEUROSCI.3890-09.2009
Conflict of Interest Statement: Alfonso Abizaid, Martin K. Wellman, and Zachary
R. Patterson hold a patent on CF801 (WO/2015/010210). All other authors have
nothing to declare.
Copyright © 2015 Wellman, Patterson, MacKay, Darling, Mani, Zigman, Hougland
and Abizaid. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Endocrinology | www.frontiersin.org September 2015 | Volume 6 | Article 14412
